— Shares of biopharmaceutical company AbbVie shed more than 1% after the CEO said at the JPMorgan Healthcare Conference that it expects the loss of exclusivity of Humira, its drug for
arthritis and psoriasis, to affect the company's performance in the near term, according to a report from Bloomberg. The company does not anticipate a decline in 2024 earnings, however.
این خبر را خلاصه کرده ایم تا بتوانید سریع آن را بخوانید. اگر به خبر علاقه مند هستید، می توانید متن کامل را اینجا بخوانید. ادامه مطلب:
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and moreThese are the stocks posting the largest moves midday.
منبع: CNBC - 🏆 12. / 72 ادامه مطلب »
UBS sees these retail stocks winning from a potential Bed Bath & Beyond bankruptcyDoubts about Bed Bath & Beyond's future opens a door for other retailers to pick up market share, says UBS
منبع: CNBC - 🏆 12. / 72 ادامه مطلب »
Bed Bath & Beyond jumps 50% to lead last gasp rally in meme stocks; AMC gains 15%A group of highly speculative stocks rallied double digits on Wednesday as retail investors pushed meme names up again in the new year following a dismal 2022.
منبع: CNBC - 🏆 12. / 72 ادامه مطلب »